Vivos Therapeutics, Inc. — Form SCHEDULE 13D
Filed July 15, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 42/100
What the filing says
Michael C. Skaff and four affiliated entities (V-CO Investors LLC, V-Co Investors 2 LLC, V-Co Investors 3 LLC, V-Co Investors 4 LLC) filed a joint Schedule 13D on July 15, 2026, establishing coordinated filing obligations for subsequent amendments. The filing is a boilerplate joint filing agreement establishing that each party will be responsible for timely filing amendments and accuracy of information concerning themselves. No specific share count, percentage ownership, or transaction details are disclosed in this exhibit; the core filing document is required to determine the actual stake and intent.
Why this rating
Joint filing agreement indicates coordinated investment activity requiring disclosure; depends entirely on undisclosed stake size. Core 13D details needed to assess materiality.
See more from July 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.